Skip to main content
Top
Published in: Indian Journal of Gastroenterology 5/2016

01-09-2016 | Original Article

Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction

Authors: Praveer Rai, Pankaj Kumar, Swapnil Mishra, Rakesh Aggarwal

Published in: Indian Journal of Gastroenterology | Issue 5/2016

Login to get access

Abstract

Background

Hepatic venous outflow tract obstruction (HVOTO) and extrahepatic portal venous obstruction (EHPVO) are important causes of portal hypertension and related complications in India. Both these conditions result from splanchnic venous thrombosis. In recent years, a V617F somatic mutation in Janus kinase 2 (JAK2) gene which is highly specific for myeloproliferative disorders has been detected in 40 % to 50 % and 30 % to 35 % of Western patients with HVOTO and EHPVO, respectively. However, data on this mutation in these conditions from Asian countries are limited.

Methods

We looked for JAK2 V617F mutation in Indian patients with HVOTO (n = 40, median age 31 [range 17–51] years, 21 female) and EHPVO (n = 50, median age 23 [15–70] years, 25 female) by using two separate methods. Both the methods involved polymerase chain reaction using allele-specific primers. Positive results on one or both of these techniques were confirmed using DNA sequencing.

Results

None of the 40 patients with HVOTO and only 1 of 50 patients with EHPVO was found to have JAK2 V617F mutation. In the one patient who was found to have this mutation, both the PCR methods and DNA sequencing showed positive results.

Conclusion

Hypercoagulability associated with JAK2 V617F mutation and associated chronic myeloproliferative disorders was not a major cause of HVOTO and EHPVO in this population.
Literature
1.
go back to reference Wani ZA, Bhat RA, Bhadoria AS, Maiwall R. Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: need for a new classification. Saudi J Gastroenterol. 2015;21:129–38.CrossRefPubMedPubMedCentral Wani ZA, Bhat RA, Bhadoria AS, Maiwall R. Extrahepatic portal vein obstruction and portal vein thrombosis in special situations: need for a new classification. Saudi J Gastroenterol. 2015;21:129–38.CrossRefPubMedPubMedCentral
2.
go back to reference Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.CrossRefPubMed Okuda H, Yamagata H, Obata H, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol. 1995;22:1–9.CrossRefPubMed
3.
go back to reference Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587–91.CrossRefPubMed Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology. 2000;31:587–91.CrossRefPubMed
4.
go back to reference De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411–8.CrossRefPubMed De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost. 1997;23:411–8.CrossRefPubMed
5.
go back to reference Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553–60.CrossRefPubMed Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553–60.CrossRefPubMed
6.
go back to reference Primignani M, Martinelli I, Bucciarelli P. Risk factors for thrombophilia in extrahepatic protal vein obstruction. Hepatology. 2005;41:603–8.CrossRefPubMed Primignani M, Martinelli I, Bucciarelli P. Risk factors for thrombophilia in extrahepatic protal vein obstruction. Hepatology. 2005;41:603–8.CrossRefPubMed
7.
go back to reference Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J. Case records of the Massachusetts General Hospital. Case 15–2006: a 46-year-old woman with sudden onset of abdominal distension. N Engl J Med. 2006;354:2166–75.CrossRefPubMed Chung RT, Iafrate AJ, Amrein PC, Sahani DV, Misdraji J. Case records of the Massachusetts General Hospital. Case 15–2006: a 46-year-old woman with sudden onset of abdominal distension. N Engl J Med. 2006;354:2166–75.CrossRefPubMed
9.
go back to reference Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063–9.CrossRefPubMed Valla D, Casadevall N, Huisse MG, et al. Etiology of portal vein thrombosis in adults: a prospective evaluation of primary myeloproliferative disorders. Gastroenterology. 1988;94:1063–9.CrossRefPubMed
10.
go back to reference Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985;103:329–34.CrossRefPubMed Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis: a prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med. 1985;103:329–34.CrossRefPubMed
11.
go back to reference Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed Kralovics R, Passamonti F, Buser AS, et al. A gain of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed
12.
go back to reference Baxter EJ, Scott LM, Campbell PJ, et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed Baxter EJ, Scott LM, Campbell PJ, et al. Cancer genome project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed
13.
go back to reference Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed
14.
go back to reference Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207–9.CrossRefPubMedPubMedCentral Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207–9.CrossRefPubMedPubMedCentral
15.
go back to reference Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849GT is rare in acute leukemias but can be found in CMML, Philadelphia chromosome negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370–3.CrossRefPubMedPubMedCentral Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849GT is rare in acute leukemias but can be found in CMML, Philadelphia chromosome negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370–3.CrossRefPubMedPubMedCentral
16.
go back to reference Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.CrossRefPubMed Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology. 2006;44:1528–34.CrossRefPubMed
17.
go back to reference Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinol. 2008;19:459–62.CrossRef Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome. Blood Coagul Fibrinol. 2008;19:459–62.CrossRef
18.
go back to reference Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–9.CrossRefPubMed Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111:4922–9.CrossRefPubMed
19.
go back to reference Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.CrossRefPubMed Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162–8.CrossRefPubMed
20.
go back to reference Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hemopoietic stem cell defects in Budd–Chiari syndrome. J Hepatol. 1997;26:293–7.CrossRefPubMed Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hemopoietic stem cell defects in Budd–Chiari syndrome. J Hepatol. 1997;26:293–7.CrossRefPubMed
21.
go back to reference Dhiman P, Saxena P. JAK2V617F: is it sufficient as a single player in splanchnic venous thrombosis? Case Rep Hematol. 2015;2015:373490.PubMedPubMedCentral Dhiman P, Saxena P. JAK2V617F: is it sufficient as a single player in splanchnic venous thrombosis? Case Rep Hematol. 2015;2015:373490.PubMedPubMedCentral
22.
go back to reference Dasari S, Naha K, Hande M, Vivek G. A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis. BMJ Case Rep. 2013; 2013. Dasari S, Naha K, Hande M, Vivek G. A novel subtype of myeloproliferative disorder? JAK2V617F-associated hypereosinophilia with hepatic venous thrombosis. BMJ Case Rep. 2013; 2013.
23.
go back to reference Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–85.CrossRefPubMedPubMedCentral Amarapurkar DN, Punamiya SJ, Patel ND. Changing spectrum of Budd-Chiari syndrome in India with special reference to non-surgical treatment. World J Gastroenterol. 2008;14:278–85.CrossRefPubMedPubMedCentral
24.
go back to reference Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–5.CrossRefPubMed Shetty S, Kulkarni B, Pai N, Mukundan P, Kasatkar P, Ghosh K. JAK2 mutations across a spectrum of venous thrombosis cases. Am J Clin Pathol. 2010;134:82–5.CrossRefPubMed
25.
go back to reference Sazawal S, Rathi S, Chikkara S, et al. JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India. Indian J Med Res. 2012;135:429–31.PubMedPubMedCentral Sazawal S, Rathi S, Chikkara S, et al. JAK2 mutation in patients with splanchnic venous thrombosis: a pilot study from India. Indian J Med Res. 2012;135:429–31.PubMedPubMedCentral
26.
go back to reference Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N. Prevalence of JAK2-V617F mutation in intra-abdominal venous thrombosis. Trop Gastroenterol. 2011;32:279–84.PubMed Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N. Prevalence of JAK2-V617F mutation in intra-abdominal venous thrombosis. Trop Gastroenterol. 2011;32:279–84.PubMed
27.
go back to reference Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd–Chiari syndrome. Hepatology. 2004;39:500–8.CrossRef Murad SD, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd–Chiari syndrome. Hepatology. 2004;39:500–8.CrossRef
28.
go back to reference Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with177 patients and review of the literature. Medicine (Baltimore). 1994;73:21–36.CrossRef Dilawari JB, Bambery P, Chawla Y, et al. Hepatic outflow obstruction (Budd-Chiari syndrome): experience with177 patients and review of the literature. Medicine (Baltimore). 1994;73:21–36.CrossRef
29.
go back to reference Kumar SI, Kumar A, Srivastava S, Saraswat VA, Aggarwal R. Low frequency of factor V Leiden and prothrombin G20210 A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study. Indian J Gastroenterol. 2005;24:211–5.PubMed Kumar SI, Kumar A, Srivastava S, Saraswat VA, Aggarwal R. Low frequency of factor V Leiden and prothrombin G20210 A mutations in patients with hepatic venous outflow tract obstruction in northern India: a case-control study. Indian J Gastroenterol. 2005;24:211–5.PubMed
30.
go back to reference Singh V, Sinha SK, Nain CK, et al. Budd-Chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol. 2000;15:550–4.CrossRefPubMed Singh V, Sinha SK, Nain CK, et al. Budd-Chiari syndrome: our experience of 71 patients. J Gastroenterol Hepatol. 2000;15:550–4.CrossRefPubMed
31.
go back to reference Abd-El-Hamid N, Taylor RM, Marinello D, et al. Aetiology and management of extrahepatic portal vein obstruction in children: King’s College Hospital experience. J Pediatr Gastroenterol Nutr. 2008;47:630–4.CrossRefPubMed Abd-El-Hamid N, Taylor RM, Marinello D, et al. Aetiology and management of extrahepatic portal vein obstruction in children: King’s College Hospital experience. J Pediatr Gastroenterol Nutr. 2008;47:630–4.CrossRefPubMed
32.
go back to reference Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364–8.PubMed Janssen HL, Meinardi JR, Vleggaar FP, et al. Factor V Leiden mutation prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364–8.PubMed
33.
go back to reference Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd–Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol. 2004;121:844–7.CrossRefPubMed Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd–Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol. 2004;121:844–7.CrossRefPubMed
34.
go back to reference Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd–Chiari syndrome: a study from western India. Hepatology. 2001;34:666–70.CrossRefPubMed Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd–Chiari syndrome: a study from western India. Hepatology. 2001;34:666–70.CrossRefPubMed
36.
37.
go back to reference Yadav S, Dutta AK, Sarin SK. Do umbilical vein catheterization and sepsis lead to portal vein thrombosis? A prospective, clinical and sonographic evaluation. J Pediatr Gastroenterol Nutr. 1993;17:392–6.CrossRefPubMed Yadav S, Dutta AK, Sarin SK. Do umbilical vein catheterization and sepsis lead to portal vein thrombosis? A prospective, clinical and sonographic evaluation. J Pediatr Gastroenterol Nutr. 1993;17:392–6.CrossRefPubMed
39.
go back to reference Pinto RB, Silveira TR, Bandenilli E, Rohsig L. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg. 2004;39:1356–61.CrossRefPubMed Pinto RB, Silveira TR, Bandenilli E, Rohsig L. Portal vein thrombosis in children and adolescents: the low prevalence of hereditary thrombophilic disorders. J Pediatr Surg. 2004;39:1356–61.CrossRefPubMed
40.
go back to reference Sharma S, Kumar SI, Poddar U, Yachha SK, Aggarwal R, Factor V. Leiden and prothrombin gene G20210 A mutations are uncommon in portal vein thrombosis in India. Indian J Gastroenterol. 2006;25:236–9.PubMed Sharma S, Kumar SI, Poddar U, Yachha SK, Aggarwal R, Factor V. Leiden and prothrombin gene G20210 A mutations are uncommon in portal vein thrombosis in India. Indian J Gastroenterol. 2006;25:236–9.PubMed
41.
go back to reference Seixas CA, Hessel G, Ribeiro CC, Arruda VR, Annichino-Bizzacchi JM, Factor V. Leiden is not common in children with portal vein thrombosis. Thromb Haemost. 1997;77:258–61.PubMed Seixas CA, Hessel G, Ribeiro CC, Arruda VR, Annichino-Bizzacchi JM, Factor V. Leiden is not common in children with portal vein thrombosis. Thromb Haemost. 1997;77:258–61.PubMed
42.
go back to reference Seixas CA, Hessel G, Siqueira LH, Machado TF, Gallizoni AM, Annichino-Bizzacchi JM. Study of hemostasis in pediatric patients with portal vein thrombosis. Haematologica. 1998;83:955–6.PubMed Seixas CA, Hessel G, Siqueira LH, Machado TF, Gallizoni AM, Annichino-Bizzacchi JM. Study of hemostasis in pediatric patients with portal vein thrombosis. Haematologica. 1998;83:955–6.PubMed
Metadata
Title
Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction
Authors
Praveer Rai
Pankaj Kumar
Swapnil Mishra
Rakesh Aggarwal
Publication date
01-09-2016
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 5/2016
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-016-0691-7

Other articles of this Issue 5/2016

Indian Journal of Gastroenterology 5/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.